HHG & Company’s AstraZeneca AZN Stock Holding History

HHG & Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$649K	Sell	11,522 -162	-1%	-$9.73K	0.18%	110
2015 Q4	$793K	Buy	11,684 +43	+0.4%	+$2.82K	0.21%	103
2015 Q3	$741K	Sell	11,641 -30	-0.3%	-$1.97K	0.22%	103
2015 Q2	$744K	Sell	11,671 -95	-0.8%	-$6.5K	0.21%	106
2015 Q1	$805K	Buy	11,766 +57	+0.5%	+$3.96K	0.21%	106
2014 Q4	$824K	Buy	11,709 +180	+2%	+$12.9K	0.2%	112
2014 Q3	$824K	Buy	11,529 +29	+0.3%	+$2.12K	0.27%	93
2014 Q2	$855K	Sell	11,500 -7,670	-40%	-$554K	0.28%	106
2014 Q1	$1.24M	Sell	19,170 -165	-0.9%	-$10.7K	0.42%	84
2013 Q4	$1.14M	Sell	19,335 -230	-1%	-$12.5K	0.42%	82
2013 Q3	$1.02M	Sell	19,565 -20	-0.1%	-$1K	0.41%	89
2013 Q2	$930K	Buy	+19,585	New	+$997K	0.38%	93

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

HHG & Company's AZN Position: Q1 2016 in Review

HHG & Company reduced its AstraZeneca (AZN) stake by 1.4% in Q1 2016, selling an estimated $9.73K and leaving 11,522 shares worth $649K. The position accounts for 0.18% of the portfolio, ranked #110.

HHG & Company first reported a position in AZN in Q2 2013 and has held it in 12 quarters since. The position peaked at $1.24M in Q1 2014. 390 funds tracked by Wall St. Rank hold AZN as of Q1 2016.

HHG & Company held 11,522 shares of AstraZeneca worth $649K as of Q1 2016.
HHG & Company sold 162 AstraZeneca shares in Q1 2016, an estimated $9.73K.
AstraZeneca made up 0.18% of HHG & Company's portfolio in Q1 2016, its #110 holding.
HHG & Company first reported a position in AstraZeneca in Q2 2013 and has held it in 12 quarters since.
HHG & Company's AstraZeneca position peaked at $1.24M in Q1 2014.
390 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2016.

Based on HHG & Company's 13F filing for Q1 2016, filed 20 Apr 2016.